The next portion of Dr. Leighl's "Highlights of Lung Cancer from 2012" webinar focused on exciting research presented at ASCO 2012 and very recently published on the potential efficacy of a new class of targeted therapy, called MEK inhibitors, for the large subset of patients who have a KRAS mutation. KRAS is the most common mutation seen in lung cancer, found in about 20-25% of patients with NSCLC, in different histologies and with different smoking histories, but we haven't had an effective therapy for this group of patients, in whom some evidence suggests that both EGFR inhibitors and standard chemotherapy are less effective.
Dr. Leighl's podcast discusses encouraging work that suggests a potential value in adding a MEK inhibitor to standard chemo, though ensuring that it's a tolerable combination is something we'll need to continue to work on (in addition to confirming the activity of MEK inhibitors in larger trials). Here's her presentation in video and audio format, as well as the figures for it.
Dr. Leighl's Highlights in Lung Cancer, 2012 program next turned to squamous cell carcinoma and anti-PD1 immunotherapy work, so look for that here very soon. In the meantime, I hope you find this program helpful and promising!
Hi Oaktowngrrl, Welcome to Grace. I'm so sorry you're going through this.
Finding a reputable dedicated thoracic surgeon for lung surgery might be difficult, as it is a complex and...
Hello Hello, Just want to let you know I see your post and will respond more appropriately in the morning.
I'm sure you're…